The reduction in price target by B. Riley Securities suggests that while the firm remains optimistic about NGM Biopharmaceuticals' long-term prospects, it acknowledges near-term challenges or potential overvaluation at the previous target price. This could lead to a negative short-term impact on the stock price as investors adjust their expectations.